title: Management and prognosis in synchronous solitary resected brain metastasis from non-small-cell lung cancer.
abstract: BACKGROUND
  Reports in the medical literature have described cases of extended survival of patients with non-small-cell lung cancer (NSCLC) with solitary metastatic disease who have received aggressive treatment both to the brain metastasis and to the local/regional disease. The objective of this research is to analyze prognostic factors that predict for outcome in this unique patient population.
  
  
  METHODS
  A single-institution, retrospective chart review was performed on 35 patients with NSCLC and a synchronous solitary brain metastasis (SSBM) treated with craniotomy and whole-brain radiation therapy. Eight patients (22.9%) had chest surgery, 24 (68.6%) had chemotherapy, and 14 (40%) had thoracic radiation as part of their local management. Fourteen had stage I/II disease (42.9%), and 20 had stage III disease (57.1%). Mean age at diagnosis was 58.5 years. Eighteen patients (56.25%) had a brain metastasis < 3 cm, and 14 patients (43.75%) had a metastasis > 3 cm.
  
  
  RESULTS
  Median survival was 7.8 months, and at last follow-up, 3 patients (8.6%) were alive and well, 6 patients (17.1%) were alive and with disease, 24 patients (68.6%) had died of disease, and 2 patients (5.7%) had died of other causes. Univariate analysis demonstrated that lung surgery (P = .0033), primary lung treatment > 8 weeks after brain surgery (P = .0128), and stage I/II disease (P = .0467) were predictive of overall survival.
  
  
  CONCLUSIONS
  Survival remains poor for patients with NSCLC with an SSBM. However, patients with thoracic disease amenable to local resection should be considered for such therapy because a survival advantage could exist compared with patients with more locally advanced disease.
authors.affiliation: Department of Radiation Oncology, London Regional Cancer Program, London, Ontario, Canada.
authors.forename: Alexander V
authors.initials: AV
authors.lastname: Louie
authors.forename: George
authors.initials: G
authors.lastname: Rodrigues
authors.forename: Brian
authors.initials: B
authors.lastname: Yaremko
authors.forename: Edward
authors.initials: E
authors.lastname: Yu
authors.forename: A Rashid
authors.initials: AR
authors.lastname: Dar
authors.forename: Brian
authors.initials: B
authors.lastname: Dingle
authors.forename: Mark
authors.initials: M
authors.lastname: Vincent
authors.forename: Michael
authors.initials: M
authors.lastname: Sanatani
authors.forename: Jawaid
authors.initials: J
authors.lastname: Younus
authors.forename: Richard
authors.initials: R
authors.lastname: Malthaner
authors.forename: Richard
authors.initials: R
authors.lastname: Inculet
mesh_terms: D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D016371:Cranial Irradiation; D006801:Humans; D007223:Infant; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies